Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.

ABSTRACT:

Objective

Identify serum biomarkers modulated by golimumab treatment and associated with clinical response in patients with ankylosing spondylitis (AS).

Methods

Sera were collected at weeks 0, 4 and 14 from 100 patients with active AS in the GO-RAISE study. Patients were randomly assigned subcutaneous injections of placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks. Samples were tested for select inflammatory, bone and cartilage markers, and protein profiling was also performed.

Results

Golimumab treatment resulted in significant decreases in several serum proteins at weeks 4 and 14 compared with placebo. Patients who achieved clinical response at week 14, as assessed by a ≥20% improvement in the Assessment in SpondyloArthitis international Society response c

SUBMITTER: Wagner C 

PROVIDER: S-EPMC3329231 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature